Reviparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Reviparin
Accession Number
DB09259
Type
Small Molecule
Groups
Approved, Investigational
Description

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.1 It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.2 It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.3

Synonyms
  • Reviparin sodium
Categories
UNII
5XQ9UBJ16W
CAS number
9041-08-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

By the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients.3

Pharmacodynamics

Reviparin is been shown to present significant inhibition of smooth muscle cell migration and proliferation in human cell cultures without affecting endothelial cell growth.1

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(1,2,6,7-3H)Testosterone(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Reviparin.
(R)-warfarinThe risk or severity of bleeding can be increased when Reviparin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Reviparin is combined with (S)-Warfarin.
1-Testosterone1-Testosterone may increase the anticoagulant activities of Reviparin.
18-methyl-19-nortestosterone18-methyl-19-nortestosterone may increase the anticoagulant activities of Reviparin.
3,5-Diiodotyrosine3,5-Diiodotyrosine may increase the anticoagulant activities of Reviparin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Reviparin is combined with 4-hydroxycoumarin.
4-Hydroxytestosterone4-Hydroxytestosterone may increase the anticoagulant activities of Reviparin.
5beta-dihydrotestosterone5beta-dihydrotestosterone may increase the anticoagulant activities of Reviparin.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Reviparin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol. 1996 Nov 15;28(6):1437-43. [PubMed:8917255]
  2. Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S: Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol. 2000 Apr;49(4):337-41. [PubMed:10759689]
  3. FDA orphan list [Link]
External Links
KEGG Drug
D03337
PubChem Substance
347910423
Wikipedia
Reviparin_sodium
ATC Codes
B01AB08 — Reviparin
MSDS
Download (52.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentNeoplasms / Venous Thromboembolism (VTE)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility50 mg/ml'MSDS'
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 10:53 / Updated on November 02, 2019 02:36